TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20032168

Group type: EXPERIMENTAL
Intervention: Lessons in the Alexander Technique
Number of subjects: 359

Group type: COMPARATOR
Intervention: Exercise prescription
Number of subjects: 359
Study: 17011601

Group type: EXPERIMENTAL
Intervention: Frontal brain function and positive symptom schizotypy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Posterior brain function and low positive affect
Number of subjects: 36
Study: 15563538

Group type: EXPERIMENTAL
Intervention: Indomethacin (COX-1 and COX-2 inhibitor)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Celecoxib (COX-2 inhibitor)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 12539211

Group type: EXPERIMENTAL
Intervention: Pramipexole 500 microg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pergolide 500 microg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10628188

Group type: EXPERIMENTAL
Intervention: DASH diet (8-10 fruits and vegetables and 2-3 low-fat dairy foods per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 8607762

Group type: EXPERIMENTAL
Intervention: Constant angle contract-relax stretch
Number of subjects: 10

Group type: COMPARATOR
Intervention: Static stretch
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Variable angle contract-relax stretch
Number of subjects: 10
Study: 2061535

Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sickness Impact Profile (SIP)
Number of subjects: 25
Study: 7080891

Group type: EXPERIMENTAL
Intervention: Co‐action condition (simultaneous drinking with a heavy drinking accomplice)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control observer condition (accomplice completing an art rating task)
Number of subjects: 64
Study: 30143028

Group type: EXPERIMENTAL
Intervention: Psychologically supported, patient-centred, multi-disciplinary intervention into frailty
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual haemodialysis standard of care
Number of subjects: 50
Study: 26871379

Group type: EXPERIMENTAL
Intervention: Swimming intervention (2 times/week, 40-50 minutes for 10 weeks)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Swimming intervention (after 20-week follow-up)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Swimming intervention
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study: 24560181

Group type: EXPERIMENTAL
Intervention: Oxygen saturation target of 85%-89%
Number of subjects: 340

Group type: COMPARATOR
Intervention: Oxygen saturation target of 91%-95%
Number of subjects: 340
Study: 21777924

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg/d) for 10 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 26
Study: 20842740

Group type: EXPERIMENTAL
Intervention: Poor R-wave progression (group II, n = 36)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normal R-wave progression (group I, n = 34)
Number of subjects: 70
Study: 17922972

Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin/gemcitabine (PCG)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Gemcitabine/vinorelbine
Number of subjects: 337
Study: 16320331

Group type: EXPERIMENTAL
Intervention: SELDI-TOF-MS technology for RA patients
Number of subjects: 103
Study: 12191852

Group type: EXPERIMENTAL
Intervention: Soy rich diet
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 187
Study: 9700950

Group type: EXPERIMENTAL
Intervention: Wheat amylase inhibitor (WAI) 4 g
Number of subjects: 12
Study: 7887719

Group type: EXPERIMENTAL
Intervention: Tepid cardioplegia (29 degrees C)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Warm cardioplegia (37 degrees C)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cold cardioplegia (9 degrees C)
Number of subjects: 42
Study: 2222242

Group type: EXPERIMENTAL
Intervention: Best medical management
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Surgical evacuation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intracranial pressure monitoring
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 21
Study: 360819

Group type: EXPERIMENTAL
Intervention: Essential amino acids (15.7 g daily for 3 months)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Liberal diet (1 g protein/kg body weight)
Number of subjects: 13
Study: 31243158

Group type: EXPERIMENTAL
Intervention: Interactive SR teddy bear
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Tablet-based avatar version of the bear
Number of subjects: 54

Group type: COMPARATOR
Intervention: Plush teddy bear with human presence
Number of subjects: 54
Study: 28260864

Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg/day or 10 mg/day plus HBO therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: HBO therapy as monotherapy
Number of subjects: 120
Study: 26198966

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 0.5 mg/kg lidocaine and 0.5 mg/kg ketamine, followed by continuous infusion of lidocaine at 0.5 mg·kg(‐1)·h(‐1) till the end of the operation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline infusion only
Number of subjects: 60
Study: 23260855

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (ethinyl E2 and desogestrel) for 9 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Transdermal patches (ethinyl E2 and norelgestromin) for 9 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Vaginal rings (ethinyl E2 and etonogestrel) for 9 weeks
Number of subjects: 42
Study: 21278401

Group type: EXPERIMENTAL
Intervention: Metronidazole (MTZ) single-dose 2 g
Number of subjects: 244
Study: 19891046

Group type: COMPARATOR
Intervention: Standard-dose cyclosporine
Number of subjects: 1645

Group type: EXPERIMENTAL
Intervention: Daclizumab induction plus low-dose cyclosporine
Number of subjects: 1645

Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus
Number of subjects: 1645

Group type: EXPERIMENTAL
Intervention: Low-dose sirolimus
Number of subjects: 1645
Study: 17403857

Group type: EXPERIMENTAL
Intervention: Human Botulism Immune Globulin
Number of subjects: 681
Study: 15482753

Group type: EXPERIMENTAL
Intervention: Piroxicam (10 mg orally) before embryo transfer in fresh cycles
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Piroxicam (10 mg orally) before embryo transfer in frozen-thawed cycles
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo before embryo transfer in fresh cycles
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo before embryo transfer in frozen-thawed cycles
Number of subjects: 188
Study: 11685412

Group type: EXPERIMENTAL
Intervention: Small apertures with varying size and shape
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Location of stimulus in the visual field
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overall duration of the stimulus
Number of subjects: 0
Study: 9778615

Group type: EXPERIMENTAL
Intervention: Ondansetron (OND) 8 mg every 6 hours for the first 24 hours (total of 4 doses)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ondansetron (OND) 32 mg as a loading dose before cisplatin, total dose for the first 24 hours
Number of subjects: 110

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 110
Study: 8880045

Group type: EXPERIMENTAL
Intervention: Draflazine 3.5 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 2397974

Group type: EXPERIMENTAL
Intervention: 10% PVP‐iodine solution and 50% salicylic acid plaster therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (lacked either one of the applications)
Number of subjects: 20
Study: 7197979

Group type: EXPERIMENTAL
Intervention: amezinium (10 mg i.v.)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: norfenefrine (10 mg i.m.)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: dihydroergotamine (1 mg i.m.)
Number of subjects: 29

Group type: COMPARATOR
Intervention: control test
Number of subjects: 29
Study: 31045821

Group type: COMPARATOR
Intervention: Desflurane anesthesia
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Propofol total intravenous anesthesia (TIVA)
Number of subjects: 50
Study: 28506548

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic medication (AAD)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Catheter ablation (CA)
Number of subjects: 260
Study: 25839374

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral nutrition
Number of subjects: 102

Group type: COMPARATOR
Intervention: Nutrition education
Number of subjects: 102
Study: 22431446

Group type: EXPERIMENTAL
Intervention: nCPAP (6 cmH2O pressure support for 6 hours)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (air/oxygen mixture from heated humidifier for 6 hours)
Number of subjects: 19
Study: 21091546

Group type: EXPERIMENTAL
Intervention: 0.2% probiotic
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: 0.3% probiotic
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: 0.5% probiotic
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: 0.1% probiotic
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: 0.2% to 0.5% probiotic
Number of subjects: 375

Group type: COMPARATOR
Intervention: Control (0% probiotic)
Number of subjects: 375
Study: 19021788

Group type: EXPERIMENTAL
Intervention: Therapies published as case reports (CRs)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 31
Study: 17556695

Group type: EXPERIMENTAL
Intervention: DHA-containing functional food (300 mg DHA/92-kcal bar; average consumption: 5 bars/wk)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (cereal-based bars)
Number of subjects: 29
Study: 15121876

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no mifepristone)
Number of subjects: 14
Study: 11448466

Group type: EXPERIMENTAL
Intervention: 50 microg/day NES
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 75 microg/day NES
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 100 microg/day NES
Number of subjects: 87
Study: 8822534

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 +/- 2.5 mg/day (Olz-M)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Olanzapine 15 +/- 2.5 mg/day (Olz-H)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Haloperidol 15 +/- 5 mg/day (Hal)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Olanzapine 5 +/- 2.5 mg/day (Olz-L)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 335
Study: 1424412

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3918734

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no naloxone)
Number of subjects: 10
Study: 31206808

Group type: EXPERIMENTAL
Intervention: TAC-ER 0.15 mg/kg/day based on adjusted body weight (aBW)
Number of subjects: 20

Group type: COMPARATOR
Intervention: TAC-ER 0.15 mg/kg/day based on ideal body weight (IBW)
Number of subjects: 20
Study: 29501363

Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m2 intravenously weekly for 12 doses) plus carboplatin (area under the curve 6 mg/mL per min, intravenously every 3 weeks, for four cycles) plus veliparib (50 mg orally, twice a day)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin
Number of subjects: 634

Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Carboplatin (with or without veliparib)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Veliparib
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 634
Study: 27922288

Group type: EXPERIMENTAL
Intervention: Immediate rehabilitation (physical therapy from day 1 to day 84)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional rehabilitation (physical therapy from day 29 to day 84)
Number of subjects: 26
Study: 24978952

Group type: EXPERIMENTAL
Intervention: RA+ (risk-assessment questionnaire plus nasal flow monitor)
Number of subjects: 325

Group type: COMPARATOR
Intervention: RAO (risk-assessment-only questionnaire)
Number of subjects: 325

Group type: COMPARATOR
Intervention: RAO
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: RA+
Number of subjects: 325
Study: 22777673

Group type: EXPERIMENTAL
Intervention: Intra-arterial ATP infusions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: KCl infusion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combined infusion of ouabain and barium chloride (BaCl2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combined ouabain plus BaCl2 infusion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BaCl2 alone
Number of subjects: 16
Study: 20362915

Group type: EXPERIMENTAL
Intervention: Conventional glass ionomer cement (GIC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer cement (RMGIC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Polyacid-modified composite
Number of subjects: 60
Study: 17568245

Group type: EXPERIMENTAL
Intervention: Red yeast rice (600 mg, twice daily for 8 weeks)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 16128784

Group type: EXPERIMENTAL
Intervention: Covered expandable metallic stents
Number of subjects: 22
Study: 12137831

Group type: EXPERIMENTAL
Intervention: Laser prostatectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 100
Study: 9973020

Group type: EXPERIMENTAL
Intervention: Forced diuresis with intravenous crystalloid, furosemide, mannitol (if pulmonary capillary wedge pressure <20 mm Hg), and low-dose dopamine (n = 43)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Intravenous crystalloid and matching placebos (n = 55)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Combined analysis of all participants
Number of subjects: 98
Study: 7568389

Group type: EXPERIMENTAL
Intervention: Experienced examiners (1 male, 1 female)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Inexperienced examiners (1 male, 1 female)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 67‐N, 89‐N, maximum manual, and active anterior drawer tests
Number of subjects: 22
Study: 1960071

Group type: EXPERIMENTAL
Intervention: Two-ETS with 100% tidal volume (VT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Two-ETS with 135% tidal volume (VT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Three-ETS with 100% tidal volume (VT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Three-ETS with 135% tidal volume (VT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 30
Study: 7072998

Group type: EXPERIMENTAL
Intervention: Enflurane, 0.3 to 0.8 per cent, and oxygen (Group 2)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Nitrous oxide, 30 to 50 per cent, and oxygen (Group 3)
Number of subjects: 61

Group type: COMPARATOR
Intervention: No inhalation agent (Group 1)
Number of subjects: 61
Study: 31225821

Group type: EXPERIMENTAL
Intervention: Theta burst repetitive transcranial magnetic stimulation (active treatment)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo control (sham treatment)
Number of subjects: 40
Study: 28863874

Group type: EXPERIMENTAL
Intervention: PTV/EPA (PTV 4mg/day and EPA 1800mg/day)
Number of subjects: 193

Group type: COMPARATOR
Intervention: PTV (PTV 4mg/day)
Number of subjects: 193
Study: 26786266

Group type: EXPERIMENTAL
Intervention: Dry packing
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Packing soaked with water
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Packing soaked with chlorhexidine gluconate and benzydamine hydrochloride
Number of subjects: 201

Group type: COMPARATOR
Intervention: No packing
Number of subjects: 201
Study: 25168853

Group type: EXPERIMENTAL
Intervention: Group tai chi program (N = 63)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Time/attention-matched education control (N = 31)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Mind-body breathing program (N = 31)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Subgroup of patients in tai chi (N = 50)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Tai chi program (N = 63)
Number of subjects: 125
Study: 22520304

Group type: EXPERIMENTAL
Intervention: Evaluation tool for assessing surgical technique of capsulorhexis
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Visual Likert-scale questions grading flow of operation, set up for regrasp, commencement of flap and formation, and circular completion of the CCC
Number of subjects: 6
Study: 19251584

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (440 microg twice daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral montelukast (10 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 12
Study: 17237724

Group type: EXPERIMENTAL
Intervention: Folate supplementation in combination with other treatments for IBD
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Crohn's disease (CD)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ulcerative colitis (UC)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Blood lymphocytes in UC patients
Number of subjects: 41
Study: 15764422

Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 40 mg fluoxetine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg and 40 mg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 150
Study: 11270907

Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Middle-aged women
Number of subjects: 2

Group type: COMPARATOR
Intervention: Middle-aged group
Number of subjects: 2
Study: 9721958

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for 3 days
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 169
Study: 7988776

Group type: EXPERIMENTAL
Intervention: 7-hour local hyperglycaemia (5% glucose infusion)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl infusion)
Number of subjects: 12
Study: 2971693

Group type: EXPERIMENTAL
Intervention: Topical isotretinoin (0.05%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical tretinoin (0.05%)
Number of subjects: 0
Study: 31125055

Group type: EXPERIMENTAL
Intervention: 200 μg vaccine (month regimen)
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: 100 μg vaccine (month regimen)
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: month regimen
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: day regimen
Number of subjects: 855

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 855
Study: 31086354

Group type: EXPERIMENTAL
Intervention: Enhanced nutrient supply
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 28024163

Group type: EXPERIMENTAL
Intervention: Psychoeducation group (PEG) intervention program, delivered weekly in a group format over 3 weeks
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Psychoeducation group (PEG) intervention program
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 72
Study: 25926006

Group type: EXPERIMENTAL
Intervention: Large portion size (two-thirds of a cucumber)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Small portion size (one-third of a cucumber)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Large unit size (one piece of cucumber)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Small unit size (pre-sliced cucumber)
Number of subjects: 255
Study: 22676906

Group type: EXPERIMENTAL
Intervention: Surface neuromuscular electrical stimulation for 30 minutes, twice a day for 6 weeks in addition to standardized upper limb therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standardized upper limb therapy alone
Number of subjects: 90
Study: 20443105

Group type: EXPERIMENTAL
Intervention: Leukocyte esterase reagent (LER) strip test with purple-color cut-off (>500 PMNL/microL)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Leukocyte esterase reagent (LER) strip test with light-blue color cut-off (>125 PMNL/microL)
Number of subjects: 175
Study: 18029341

Group type: EXPERIMENTAL
Intervention: Nasaleze cellulose with powdered garlic extract (PGE)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (Nasaleze cellulose alone)
Number of subjects: 52
Study: 16202939

Group type: EXPERIMENTAL
Intervention: Advance supply of emergency contraception (AEC)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (information only)
Number of subjects: 160
Study: 12369021

Group type: EXPERIMENTAL
Intervention: Periodic personal provision of clinically based information at 15-minute intervals during ED visit
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Periodic personal provision of clinically based information
Number of subjects: 619

Group type: COMPARATOR
Intervention: Standard of care (no additional information provided)
Number of subjects: 619
Study: 10197566

Group type: EXPERIMENTAL
Intervention: 4500 RE (15000 IU) vitamin A/d for ≤ 12 years (group A)
Number of subjects: 146

Group type: COMPARATOR
Intervention: 23 RE (75 IU)/d (trace group)
Number of subjects: 146
Study: 7790695

Group type: EXPERIMENTAL
Intervention: Vitamin E (500 mg daily for 1 year)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (identical appearance tablets for 1 year)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Vitamin E and Placebo
Number of subjects: 67
Study: 2193075

Group type: EXPERIMENTAL
Intervention: 5-ASA 500 mg suppositories (Asacol) 3 times a day for 1 month
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo given in the same regime
Number of subjects: 62
Study: 154749

Group type: EXPERIMENTAL
Intervention: Natural oestrogen preparation (piperazine oestrone sulphate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scopolamine (control group)
Number of subjects: 0